Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

-- Phase 3 hypothalamic obesity top-line data expected in 1H2025 -- -- Positive reimbursement decision achieved for IMCIVREE® to treat patients with Bardet-Biedl syndrome and POMC/LEPR...

Related Keywords

United Kingdom ,United States ,Boston ,Massachusetts ,Spain ,Adam Daley ,Yann Mazabraud ,David Connolly ,David Meeker ,Corporate Communications ,United Kingdom Medicines Healthcare Products Regulatory Agency ,Berry Company Public Relations ,European Union ,Company Investigational New Drug ,Head Of International At Rhythm ,European Commission ,Exchange Commission ,Rhythm Pharmaceuticals ,Nasdaq ,Ministry Of Health ,Rhythm Pharmaceuticals Inc ,Chief Executive Officer ,Reimbursement Decisions Achieved ,Executive Vice President ,Investigational New Drug ,Healthcare Products Regulatory Agency ,Prescribing Information ,Important Safety ,Private Securities Litigation Reform Act ,Quarterly Report ,Investor Relations ,Markets ,